albumin-bound paclitaxel + cisplatin + tislelizumab

This is a combination therapy regimen comprising albumin-bound paclitaxel (also known as nab-paclitaxel), cisplatin, and tislelizumab. Albumin-bound paclitaxel is a solvent-free formulation of paclitaxel that utilizes albumin nanoparticle technology to deliver paclitaxel, avoiding the toxicities associated with solvents used in standard paclitaxel formulations. It has been approved for treating metastatic breast cancer, locally advanced or metastatic non-small-cell lung cancer, and metastatic pancreatic cancer. Cisplatin is a chemotherapy agent. Tislelizumab is an anti-PD-1 monoclonal antibody immunotherapy agent. This regimen would represent a combination of chemotherapy (paclitaxel and cisplatin) with immunotherapy (tislelizumab). The provided search results do not contain specific information about the clinical development status, efficacy, or safety profile of this exact three-drug combination.